Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Rexin-G: Phase I/II started

In July, Epeius began an open-label, U.S. Phase I/II

Read the full 93 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE